Вы искали: underlying disease (Английский - Словенский)

respiratory diseases (underlying lung disease)
bolezni dihal (osnovne bolezni pljuč)

underlying diseases
osnovne bolezni

this may relate to the patients underlying disease.
to je morda povezano z osnovno boleznijo bolnikov.

pyoderma is often secondary to an underlying disease.
pioderma je pogosto sekundarni klinični znak osnovne bolezni.

these symptoms may also be due to the underlying disease
psihiatrične motnje pogosti: somnolenca, nespečnost občasni: zmedenost, halucinacije redki: manične reakcije, agitacija, anksioznost, depersonalizacija, napadi panike, akatizija (glejte poglavje 4. 4 posebna opozorila in previdnostni ukrepi) ti simptomi so lahko tudi posledica osnovne bolezni.

these disorders are also associated with the underlying disease.
ti dve motnji sta prav tako povezani z boleznijo.

6 subjects who are already immunosuppressed by their underlying disease.
4. 6 nosečnost in dojenje

these responses were seen in patients independent of the underlying disease.
te odzive so opazili pri bolnikih neodvisno od osnovne bolezni.

4 these types of reactions can also be related to the underlying disease.
4 te vrste reakcij so lahko tudi posledica osnovne bolezni.

it is recommended that treatment be continued until progression of the underlying disease.
zdravljenje je priporočljivo nadaljevati do napredovanja osnovne bolezni.

the risk is increased in subjects who are already immunosuppressed by their underlying disease.
tveganje je povečano pri ljudeh, ki imajo že zaradi svoje osnovne bolezni oslabljeno delovanje imunskega sistema.

it is recommended that cetuximab treatment be continued until progression of the underlying disease.
priporočljivo je, da z zdravljenjem s cetuksimabom nadaljujete do napredovanja osnovne bolezni.

these side effects may be due to the treatment or effects resulting from the underlying disease.
ta neželena učinka sta lahko posledica zdravljenja ali posledica osnovne bolezni.

patients being treated with dabigatran have underlying disease states that predispose them to thromboembolic events.
bolniki, zdravljeni z dabigatranom, imajo osnovna bolezenska stanja, ki povečujejo nagnjenost za tromboembolične dogodke.

adverse events related to oxyglobin and/or the underlying disease causing anaemia have been observed.
opazili so neželene pojave v zvezi z oxyglobinom in/ali osnovno boleznijo, ki povzroča anemijo.

it is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.
priporočamo, da se zdravljenje nadaljuje, dokler osnovna bolezen ne napreduje ali do nesprejemljive toksičnosti.

the adverse reactions listed may also be associated with the underlying disease and / or concomitant medicinal products.
našteti neželeni učinki so lahko povezani tudi z osnovno boleznijo in/ali sočasno uporabljenimi zdravili.

all patients reported risk factors for prca such as parvovirus b19 infection, underlying disease or concomitant medications associated with prca.
pri vseh bolnikih so bili prisotni dejavniki tveganja za čisto aplazijo eritrocitov, kot so okužba s parvovirusom b19, druga bolezen ali sočasno jemanje zdravil, povezanih s

duration of therapy should be based on the severity of the underlying disease, recovery from immunosuppression, and clinical response.
trajanje terapije je odvisno od stopnje jakosti bolnikove osnovne bolezni, okrevanja po imunosupresiji in bolnikovega kliničnega odziva.

in the fourth patient, who had less severe underlying disease, spontaneous resolution occurred shortly after the infusion was interrupted.
Četrti bolnik, ki je imel manj hudo obstoječo bolezen, je kmalu po prekinitvi infundiranja spontano okreval.